Wuhan Easy Diagnosis Biomedicine Co.,ltd.

On April 15, Wuhan Easy Diagnosis Biomedicine released its first quarter results forecast for 2022

 

Performance forecast period:

January 1, 2022, to March 31, 2022

Projected performance: up in the same direction

 

Forecast interpretation:

1. Since January 2022, the outbreak of Omicron in many places in China, and the number of domestic cases has reached a record high. To prevent and control the epidemic, localities have increased the frequency of Omicron detection, and increased the demand for COVID-19 nucleic acid detection reagents. As company’s keep holding high market share in these area, revenue of related products grows significantly.

 

2. In March 2022, the comprehensive team of the State Council's joint prevention and control mechanism for the COVID-19 decided to add antigen testing as a supplement. On March 15, 2022, the company approved the COVID-19 antigen detection kit in China and successively won bids in many provinces across the country. As a result, epidemic prevention policy brought to increase the operating performance of related products.

 

3. Since January 2022, the overseas market demand for COVID-19 antigen detection kits has increased, and the company's COVID-19 antigen detection kit export orders have significantly increased year-on-year.

 

Shenzhen YHLO Biotech Co.,Ltd.

 

On April 15, Shenzhen YHLO Biotech released the first quarter results forecast for 2022

 

Performance forecast period:

January 1, 2022, to March 31, 2022

Projected performance: up in the same direction

 

In the first quarter of 2022, the net profit attributable to owners of the parent company was CNY 450 million to CNY 500 million, an increase of 1,094.75% to 1,227.50% compared with the same period last year. Net profit attributable to owners of the parent company excluding non-recurring gains and losses was CNY 440 million to CNY 498 million, representing a year-on-year increase of 1,189.00% to 1,332.86%.

 

Forecast interpretation:

 

From the end of 2021 to the end of the reporting period, the company's COVID-19 antigen detection kit (colloidal gold method) has successively obtained EU CE certification, Japan's PMDA certification designated supplier, and the National Medical Products Administration's medical device registration certificate. Japan, China (including Hong Kong) and other markets have achieved sales, and the sales revenue of this product has increased, resulting in a substantial increase in the company's performance in the first quarter of 2022 compared with the same period last year.

 

Beijing Acrobiosystems CO.,LTD.

 

On April 15, Beijing Acrobiosystems released its first quarter results forecast for 2022.

 

Performance forecast period:

January 1, 2022, to March 31, 2022

Projected performance: up in the same direction

 

Forecast interpretation:

 

By improving the company's management level and establishing a sound marketing network, the company will enhance its comprehensive competitiveness and enhance its profitability. With the joint efforts of all employees of the company, it is estimated that the operating income in the first quarter of 2022 will be CNY 111 million to CNY 117 million, a year-on-year increase of 24.09%-30.80%.

 

The company expects the revenue of non-coronavirus-related products in the first quarter of 2022 to be CNY 89 million to CNY 92 million, a year-on-year increase of 43.33%-48.16%.

 

The company expects that the sales revenue of COVID-19 virus epidemic prevention related products in the first quarter of 2022 will be CNY 22 million yuan to CNY 25 million yuan, a year-on-year decrease of 8.62%-19.58%.